Microstent favoured in France
This article was originally published in Clinica
Executive Summary
The AVE Microstent has captured around 26% of the UK market and a significant share of the European market. Dr Bernard Vales' group, from the UCV in Marseille and ICV Paris Sud, France, now use the AVE stent in 90% of stenting procedures. He explained that the multi-length family of stents is much more adaptable to different lesions than other designs. In fact his praise was so glowing that one American member of the audience was led to ask why the Europeans used any other stent. The Palmaz-Schatz stent is used by Dr Vales' group in 5.6%.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.